Unravelling the anti-cancer mechanisms elicited by non-covalent thioredoxin reductase inhibitors for triple negative breast cancer therapy.
Abigail Rullo, Brenna Flowers, Keacha Chang, An Zhang, Valentina Z. Petukhova, Luke N. M. Harding, Sammy Y. Aboagye, Maurizio Bocchetta, Wei Qiu, David Lee Williams, Francesco Angelucci, Pavel A. Petukhov, Irida Kastrati
This study identifies non-covalent TXNRD inhibitors that block TNBC cell proliferation by depleting deoxynucleotides and inhibiting ribonucleotide reductase, challenging the pro-oxidant mechanism paradigm.
Redox Biology · Dec 20, 2025Peer-reviewedCancer Biology